Meeting
2020 ASCO Virtual Scientific Program
Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study.
Authors
Karen Anne Cadoo
Memorial Sloan Kettering Cancer Center, New York, NY
Karen Anne Cadoo , Fiona Simpkins , Cara Amanda Mathews , Nashwa Kabil , James Bennett , Carol Aghajanian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02983799
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6013)
DOI
10.1200/JCO.2020.38.15_suppl.6013
Abstract #
6013
Poster Bd #
184
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.
First Author: Cara Amanda Mathews
Poster
2017 ASCO Annual Meeting
A phase 2 study to assess olaparib by homologous recombination deficiency status in patients with platinum-sensitive, relapsed, ovarian, fallopian tube, or primary peritoneal cancer.
First Author: Karen Anne Cadoo
Poster
2020 ASCO Virtual Scientific Program
Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.
First Author: Andres Poveda
Poster
2017 ASCO Annual Meeting
Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.
First Author: Yada Kanjanapan